Administrative Procedures for Clinical Laboratory Improvement Amendments of 1988 Categorization

OMB 0910-0607

OMB 0910-0607

This ICR describes the burden to manufacturers when they request Clinical Laboratory Improvement Amendments of 1998 (CLIA) categorization of in vitro diagnostic (IVD) tests when a premarket review is not needed (for example, devices exempt from premarket notification). In these cases, FDA recommends that manufacturers submit to FDA a brief description of why CLIA categorization is requested (e.g., exempt from 510(k), name change for a previously cleared device), the name of the device, the package insert (instructions for use), the product code, and regulation number. FDA will use the information collected to determine device complexity. There are three categories of test complexity: waived tests, moderate complexity tests, and high complexity tests. Laboratories performing only waived tests are subject to minimal regulation. Laboratories performing moderate or high complexity tests are subject to specific laboratory standards governing certification, personnel, proficiency testing, patient test management, quality assurance, quality control, and inspections.

The latest form for Administrative Procedures for Clinical Laboratory Improvement Amendments of 1988 Categorization expires 2022-11-30 and can be found here.


© 2021 OMB.report | Privacy Policy